Riskpilot← Back to searchSign inGet full accessTAKEDA AS
ASActiveOrg 980347257Lensmannslia 4, 1386 AskerWholesale of pharmaceutical and medical goods · NACE 4646Est. 199853 employeeswww.takeda.no
Revenue 2025
NOK 994,9M
-6% vs 2024
EBITDA margin
5.9%
-47% vs 2024
Equity ratio
62.0%
Financial strength
Net profit 2025
NOK 46,6M
-50% vs 2024
| Revenue | NOK 994,9M | -6% |
| EBITDA | NOK 58,7M | -47% |
| Net profit | NOK 46,6M | -50% |
| Total assets | NOK 480,9M | +3% |
| Equity | NOK 298M | +18% |
| Employees | 53 | — |
Legal name
TAKEDA AS
Org number
980347257
Legal form
Aksjeselskap
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
30. november 1998
Share capital
NOK 618 698
Employees
53 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2025-03-31
Financial year
January – December
Signatory rights
Styreleder og ett styremedlem i fellesskap, eller av daglig leder og ett styremedlem i fellesskap.
Company purpose
Forskning, utvikling, markedsføring og salg av farmasøytiske produkter og virksomhet som er relatert til dette. Formålet kan fremmes ved deltagelse eller samarbeid med andre foretak i inn- og utland.
Address
Lensmannslia 4, 1386 Asker
Email
privacyoffice@takeda.com
Website
www.takeda.no
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 2 402 543 | 2 272 557 | 2 472 980 | 2 269 140 | 2 561 200 | 2 921 619 | 2 942 105 | 1 446 132 | 1 617 574 | 1 062 814 | 994 865 |
| Staff expenses | −0 | −0 | −0 | −212 358 | −248 085 | −246 082 | −0 | −0 | −277 044 | −283 148 | −280 981 | −0 | −0 |
| EBITDA | 0 | 0 | 455 904 | 737 115 | 1 039 141 | 1 014 001 | 1 266 812 | 1 263 356 | 1 491 145 | 248 534 | 164 309 | 110 349 | 58 743 |
| Depreciation & amort. | −0 | −0 | −125 680 | −69 403 | −102 337 | −103 920 | −92 193 | −83 688 | −59 520 | −56 045 | −22 177 | −486 | −939 |
| EBIT | 0 | 0 | 330 224 | 667 712 | 936 804 | 910 081 | 1 174 619 | 1 179 668 | 1 431 625 | 192 489 | 142 132 | 109 863 | 57 804 |
| Net financials | 0 | 0 | 1 281 231 | 218 755 | −3 124 | 519 240 | 191 419 | 1 738 683 | −9 569 | 15 722 | −15 611 | 9 787 | 7 968 |
| Profit before tax | 0 | 0 | 1 611 455 | 886 467 | 933 679 | 1 429 321 | 1 366 038 | 2 918 351 | 1 422 056 | 208 210 | 126 521 | 119 650 | 65 772 |
| Tax | −0 | −0 | 73 963 | 191 136 | 329 613 | 241 217 | 270 113 | 230 587 | 312 461 | 46 656 | 27 999 | 26 562 | −0 |
| Net profit | 0 | 0 | 1 537 492 | 695 331 | 604 066 | 1 188 104 | 1 095 925 | 2 687 764 | 1 109 594 | 161 555 | 98 522 | 93 088 | 46 629 |
| Item | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | — | — | 5 467 081 | 3 185 253 | 3 705 023 | 4 623 904 | 5 830 218 | 9 148 048 | 10 263 976 | 1 239 775 | 515 340 | 466 306 | 480 900 |
| Equity | — | — | 4 746 674 | 2 344 663 | 2 946 451 | 4 130 963 | 5 228 437 | 7 915 339 | 294 774 | 456 796 | 159 236 | 252 063 | 298 046 |
| Long-term debt | 0 | 0 | 25 748 | 34 041 | 28 396 | 22 751 | 17 741 | 12 020 | 1 582 | 1 582 | 437 | 5 261 | 4 933 |
| Short-term debt | 0 | 0 | 526 158 | 766 002 | 690 976 | 430 113 | 550 212 | 1 188 388 | 9 936 009 | 752 611 | 336 170 | 190 861 | 159 865 |
| Total debt | 0 | 0 | 551 906 | 800 043 | 719 372 | 452 864 | 567 953 | 1 200 408 | 9 937 591 | 754 194 | 336 607 | 196 122 | 164 798 |
EBITDA margin
5.9%
This company
15.8%
Market median
-63% vs market
20132025
Equity ratio
62.0%
This company
38.2%
Market median
+62% vs market
20132025
Return on equity
15.6%
This company
18.4%
Market median
+15% vs market
20132025
Net profit margin
4.7%
This company
8.1%
Market median
-42% vs market
20132025
Asset turnover
2.07×
This company
1.12×
Market median
+85% vs market
20132025
Debt / equity
0.61×
This company
0.62×
Market median
+2% vs market
20132025
- Annual report 2025Filed via Brønnøysundsregistrene · Period 2024-04-01 – 2025-03-31
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2023-04-01 – 2024-03-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2022-04-01 – 2023-03-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2021-04-01 – 2022-03-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2020-04-01 – 2021-03-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2019-04-01 – 2020-03-31
- Annual report 2019Filed via Brønnøysundsregistrene · Period 2018-04-01 – 2019-03-31
- Annual report 2018Filed via Brønnøysundsregistrene · Period 2017-04-01 – 2018-03-31
- Annual report 2017Filed via Brønnøysundsregistrene · Period 2016-04-01 – 2017-03-31
- Annual report 2016Filed via Brønnøysundsregistrene · Period 2015-04-01 – 2016-03-31
- Annual report 2015Filed via Brønnøysundsregistrene · Period 2014-04-01 – 2015-03-31
- Annual report 2014Filed via Brønnøysundsregistrene · Period 2014-01-01 – 2014-12-31
- Annual report 2013Filed via Brønnøysundsregistrene · Period 2013-01-01 – 2013-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
KS Chief Executive Officer | Chief Executive Officer | 2024 | — | — |
BL Chief Executive Officer | Chief Executive Officer | 2014 | — | — |
VH Deputy Member | Deputy Member | 2022 | — | — |
TC Deputy Member | Deputy Member | 2021 | — | — |
TH Deputy Member | Deputy Member | 2022 | — | — |
JK Deputy Member | Deputy Member | 2022 | — | — |
OC Deputy Member | Deputy Member | 2021 | — | — |
ST Deputy Member | Deputy Member | 2022 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2022 | — | — | |
| Board of Directors | 2021 | — | — | |
| Board of Directors | 2023 | — | — | |
| Board of Directors | 2022 | — | — | |
| Board of Directors | 2023 | — | — | |
| Board of Directors | 2022 | — | — | |
| Board of Directors | 2021 | — | — | |
| Board of Directors | 2021 | — | — | |
| Chairman | 2022 | — | — | |
| Board of Directors | 2024 | — | — | |
| Chairman | 2019 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Individual | 100.0% | 100.0% | 2022 | |
Takeda Pharmaceuticals Int Ag | Company | 100.0% | 100.0% | 2023 |
Takeda Pharma. Int. Ag (Tpi-Z) | Company | 100.0% | 100.0% | 2024 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of TAKEDA AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Koki Sato | Chief Executive Officer | 0 companies |
| Bjørn Lie | Chief Executive Officer | 0 companies |
| Veronica Horpestad Liane | Deputy Member | 0 companies |
| Tone Cecilie Aas | Deputy Member | 0 companies |
| Tom Haugen | Deputy Member | 0 companies |
| Jenny Kristine Rosmer Ihle | Deputy Member | 0 companies |
| Ole Christian Skjennum | Deputy Member | 0 companies |
| Stian Tandberg Sveum | Deputy Member | 0 companies |
| Clara Hallén | Board of Directors | 0 companies |
| Knut Meinich Aastebøl | Board of Directors | 0 companies |
| Karolina Minda | Board of Directors | 0 companies |
| Tone Østberg | Board of Directors | 0 companies |
| Øyvind Løkeberg | Board of Directors | 0 companies |
| Christian Lorentz Storø | Board of Directors | 0 companies |
| Mona Jensen Breivik | Board of Directors | 0 companies |
| Finn Thomlevold Tennøe | Board of Directors | 0 companies |
| Duarte Joao Lourinho Marchand | Chairman | 0 companies |
| Christine Andersen | Board of Directors | 0 companies |
| Ingeborg Rossebø Borgheim | Chairman | 0 companies |